Geoffrey Uy, MD
There are several FDA-approved therapies for patients with newly diagnosed acute myeloid leukemia (AML), each of which plays a specific role in the treatment landscape, said Geoffrey Uy, MD. As more targeted therapies enter the space, Uy added that greater reliance on a patient’s molecular and cytogenetic profile will direct physicians to the best available therapy.
“It is becoming much more complicated to select the appropriate therapy for our newly diagnosed patients,” said Uy, an associate professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine in St. Louis, Siteman Cancer Center. “It is really important to risk stratify these patients upfront by using cytogenetics and molecular data to determine what the appropriate induction therapy is.”
Since April 2017, the FLT3 inhibitor midostaurin (Rydapt) has held a frontline indication for patients with newly diagnosed FLT3
-positive AML. The approval was based on data from the phase III RATIFY trial, which showed a 22% reduction in the risk of death with midostaurin combined with chemotherapy versus chemotherapy alone.1
... to read the full story